One Generic Cancer Drug Costs $35. Or $134. Or $13,000
الأصول والمواضيع المتأثرة
لماذا يهم
التحليل معروض بالإنجليزية · الترجمة العربية قيد الإعداد
US hospitals are marking up old cancer treatments, sometimes hundreds of times the Medicare price, contributing to rising health spending and insurance premium hikes.
نبرة المقال
التأثير المتوقع على السوق
Market impact analysis based on bearish sentiment with 64% confidence.
مسار الأدلة
الأدلة
مصدر التحليل بالذكاء الاصطناعي
المعرّفات التقنية
- وسم المزوّد
- groq-llama-3.1-8b-instant
- إصدار التحليل
- groq-llama-3.1-8b-instant
- معرّف المقال
- 24189
المصدر الأصلي
Hundreds of hospitals across the US are marking up old cancer treatments — in some cases hundreds of times what Medicare pays. Health spending in the US now tops $5 trillion a year with families and companies facing their steepest insurance premium hikes in years. Politicians often blame pharmaceutical companies, insurers, wasteful procedures and a bloated system too tangled to tame. But beneath those familiar explanations lies a lesser known phenomenon. In the opaque world of hospital pricing, medical systems across the country are able to turn routine, decades-old cancer drugs into money-makers, marking up cheap chemotherapy drugs as if they’re pricey new treatments. John Tozzi, Bloomberg Health Care Reporter joins to discuss. (Source: Bloomberg)
اقرأ المقال كاملاً على Bloomberg
المقال الأصلي منشور بواسطة Bloomberg في ديسمبر 18, 2025. التحليل والرؤى المقدمة من AnalystMarkets AI.